Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.79 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,459
Open 84.79
Bid (Size) 84.70 (1)
Ask (Size) 84.89 (1)
Prev. Close 84.79
Today's Range 84.79 - 84.79
52wk Range 73.31 - 109.17
Shares Outstanding 2,531,374,696
Dividend Yield 3.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
From Daiichi Sankyo
Via Business Wire

Performance

YTD
-14.5%
-14.5%
1 Month
+4.0%
+4.0%
3 Month
+6.9%
+6.9%
6 Month
+8.9%
+8.9%
1 Year
-20.3%
-20.3%

More News

Read More
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Via Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
From Merck & Co., Inc.
Via Business Wire
Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes
Via TokenRing AI
Topics Artificial Intelligence Economy
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
Via Stocktwits
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
Via Benzinga
2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off
Via StockStory
Topics Artificial Intelligence Stocks
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
Via Benzinga
Merck & Co. Inc. (NYSE:MRK) Demonstrates Dividend Strength and Sustainability
Via Chartmill
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Via Benzinga
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Via Benzinga
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
Via The Motley Fool
Topics Intellectual Property
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Via MarketMinute
Topics Artificial Intelligence
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Via StockStory
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Via MarketBeat
Topics Artificial Intelligence
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
Via MarketMinute
Topics Economy Government Stocks
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Via The Motley Fool
Topics ETFs Government World Trade
Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound
Via MarketMinute
Topics Artificial Intelligence Economy Government

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 84.79
When was Merck & Co last traded?
The last trade of Merck & Co was at 10/17/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 214.64B
How many shares of Merck & Co are outstanding?
Merck & Co has 215B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.